scispace - formally typeset
A

Ali El-Tayeb

Researcher at University of Bonn

Publications -  33
Citations -  1653

Ali El-Tayeb is an academic researcher from University of Bonn. The author has contributed to research in topics: Adenosine & Receptor. The author has an hindex of 20, co-authored 33 publications receiving 1395 citations. Previous affiliations of Ali El-Tayeb include University of Düsseldorf.

Papers
More filters
Journal ArticleDOI

Crystal Structure of the Human Ecto-5′-Nucleotidase (CD73): Insights into the Regulation of Purinergic Signaling

TL;DR: Crystal structures of the dimeric human e5NT reveal an extensive 114° conformational switch between the open and closed forms of the enzyme, which indicates that structural control of the domain movement determines the selectivity for monophosphate nucleotides.
Journal ArticleDOI

Ecto-5′-Nucleotidase (CD73)-Mediated Formation of Adenosine Is Critical for the Striatal Adenosine A2A Receptor Functions

TL;DR: CD73 is pointed to as a new target that can fine-tune A2AR activity, and a novel therapeutic target to manipulate A2 AR-mediated control of striatal function and neurodegeneration.
Journal ArticleDOI

Selective Activation of Adenosine A2A Receptors on Immune Cells by a CD73-Dependent Prodrug Suppresses Joint Inflammation in Experimental Rheumatoid Arthritis

TL;DR: An adenosine A2A receptor agonist (chet-AMP) is built that displays only the anti-inflammatory function in an animal model of rheumatoid arthritis, suggesting that phosphorylated A2AR agonists may serve as a promising new group of drugs for targeted immunotherapy of inflammation.
Journal ArticleDOI

Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors.

TL;DR: A beta,gamma-dichloromethylene modification in the triphosphate chain of 5-bromo-UTP was tolerated by all three receptor subtypes, thus opening up a new strategy to obtain ectonucleotide diphosphohydrolase- and phosphatase-resistant P2Y2, P 2Y4, and P2y6 receptor agonists.